We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth) (MP3-Youth)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01571128
Recruitment Status : Completed
First Posted : April 5, 2012
Last Update Posted : February 18, 2022
Sponsor:
Collaborators:
University of Nairobi
Impact Research & Development Organization
Information provided by (Responsible Party):
New York University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
MP3 Youth is a pilot study to evaluate the feasibility and acceptability of a gender-specific combination HIV prevention package for youth (aged 15-24) in high burden settings. The study aims to pilot a combination package of gender-specific interventions in western Kenya in a mobile health delivery format using integrated services delivery.

Condition or disease Intervention/treatment Phase
HIV Adolescent Behavior Gender Other: Male-Specific Intervention Package Other: Female-Specific Intervention Package Drug: Pre-Exposure Prophylaxis (Females) Behavioral: Cash Transfer Cohort (Females) Not Applicable

Detailed Description:

The MP3-Youth study will provide critical information for design and evaluation of combination HIV prevention intervention packages that are sensitive to gender-specific risks among this most-at-risk population in high-HIV burden African settings. Our team of biobehavioral and clinical scientists, mathematical modelers, and trial design specialists will:

Aim 1: Identify gender (sex)-specific drivers of HIV acquisition risk, including pregnancy among females, for youth in sub-Saharan Africa, and interventions to best address those risks.

Aim 2: Conduct mathematical modeling to select optimal combination intervention package components and to assess potential population-level impact.

Aim 3: In partnership with a highly-productive nongovernmental organization (NGO) that is delivering PEPFAR-funded HIV prevention services, develop and pilot a combination HIV prevention package specific for female and for male youth - 'MP3-Youth' - in Nyanza Province, Kenya.

Aim 4: Design a phase IV study protocol for testing the effectiveness of a gender-specific youth HIV prevention package in sub-Saharan Africa. We will disseminate these research protocol recommendations, and study instruments including the mathematical modeling tool, as a combination prevention intervention research toolkit.

Design: Study activities comprise systematic review and meta-analysis of the HIV prevention literature for youth in sub-Saharan Africa; development of a mathematical modeling tool; and a community-based HIV combination prevention pilot that will take place in western Kenya. These activities will culminate in a testable combination HIV prevention trial protocol for youth, which is the main study deliverable.

Population: Aim 1: Focus groups will be held with male and female youth, parents, teachers, religious and community leaders. Aim 3: Pilot study will include male and female youths (ages 15-24) from Nyanza Province, Kenya.

Deliverables: Study deliverables include selection procedures for a population-specific combination HIV prevention package; measurement instruments, mobile prevention delivery protocols, mathematical modeling tools, and a testable study trial protocol. The entire MP3-Youth Package will be placed on a web site for open access.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1215 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)
Actual Study Start Date : November 2014
Actual Primary Completion Date : March 23, 2016
Actual Study Completion Date : March 23, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Male-Specific Intervention Package
Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
 Other: Male-Specific Intervention Package
Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
Other Names:
  • HIV Counseling and Testing (HTC)
  • Facilitated linkage to care for HIV+: ART/PMTCT
  • Condoms
  • Voluntary Medical Male Circumcision (VMMC)
Experimental: Female-Specific Intervention Package
Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
 Other: Female-Specific Intervention Package
Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
Other Names:
  • HIV Counseling and Testing (HTC)
  • Facilitated linkage to care for HIV+: ART/PMTCT
  • Contraception/Family Planning (FP)
  • Pre-exposure Prophylaxis (PrEP)
  • Conditional Cash Transfer (CCT)
No Intervention: HIV Positive Cohort (Males and Females)
Behavioral data on HIV positive youth. Longitudinal Arm.
Experimental: Pre-Exposure Prophylaxis (Females)
PrEP adherence and feasibility. Longitudinal Arm.
 Drug: Pre-Exposure Prophylaxis (Females)
Females 18-24 who are out of school.
Other Names:
  • Truvada
  • Emtricitabine
  • Tenofovir disoproxil fumarate
Experimental: Cash Transfer Cohort (Females)
School attendance, behavioral data, and feasibility. Longitudinal Arm
 Behavioral: Cash Transfer Cohort (Females)
Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
Other Names:
  • Behavioral Economics
  • Conditional Cash Transfer


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Intervention Uptake (acceptability) and Coverage (feasibility) [ Time Frame: 6 months ]
    • Coverage: The proportion of youth in the community who attend each mobile event (estimated from youth population denominator)
    • Enrollment: The number of participants who consent to being enrolled in the study during each mobile event.
    • Uptake: The number of participants who choose one or more components of their tailored combination package (and which components).
    • Intervention Acceptability: Satisfaction with mobile event services


Secondary Outcome Measures :
  1. Adherence to medication (HIV+ and PrEP cohort participants only) over 12 months [ Time Frame: 12 months ]
    • Adherence to once daily Truvada (PrEP) among HIV-uninfected eligible females and patterns of adherence and sexual HIV acquisition risk exposure (PrEP cohort participants only). Measured by self-report, eCAPs, and clinical assessments; monthly for first 6 months and every 3 months for the following 6 months and DBS for analysis of TFV/FTC: TFV-DP/FTC-TP at months 2 and 9.
    • Adherence to ART for positives (HIV+ cohort participants only). Measured by self-report monthly SMS: 0, 3, 6,9,12 months). POC CD4 and baseline viral load by dried blood spot will be measured at mobile event baseline and repeated at 12 months.


Other Outcome Measures:
  1. Feasibility of administering cash transfer to keep girls in school [ Time Frame: 12 months ]
    Conditional Cash Transfer to reduce HIV risk by staying in school.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Any male or female between the ages of 15-24.
  • Able to understand spoken English or Kiswahili or Dholuo.
  • Willing to give informed consent or if younger than 18 years of age has a parent or guardian willing to provide consent in addition to the minor's assent
  • Willing to be tested for HIV.
  • Willing to get participant ID based on biometric finger scan.

Exclusion Criteria:

  • Any male or female younger than 15 or older than 24.
  • Unable to understand spoken English, or Kiswahili or Dholuo.
  • If under 18 and not an emancipated minor, unable to get parental consent.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01571128


Locations
Layout table for location information
United States, New York
New York University
New York, New York, United States, 10003
Kenya
Impact Research and Development Organization
Kisumu, Kenya
University of Nairobi
Nairobi, Kenya
Sponsors and Collaborators
New York University
University of Nairobi
Impact Research & Development Organization
Investigators
Layout table for investigator information
Principal Investigator: Irene Inwani, MD, MPH Kenyatta National Hospital: University of Nairobi, Kenya
Principal Investigator: Ann Kurth, PhD, CNM New York University
Study Director: Jasmine Buttolph, MPH New York University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: New York University
ClinicalTrials.gov Identifier: NCT01571128    
Other Study ID Numbers: 1R01AI094607-1
1R01AI094607 ( U.S. NIH Grant/Contract )
First Posted: April 5, 2012    Key Record Dates
Last Update Posted: February 18, 2022
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by New York University:
HIV
Prevention & Control
Intervention Studies
Adolescent
Gender
Combination prevention
 Pre-Exposure Prophylaxis
Cash Transfer
Medical Male Circumcision
HIV Testing
Mobile Health
Additional relevant MeSH terms:
Layout table for MeSH terms
Tenofovir
Emtricitabine
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
 Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents